Phone: 1.510.856.5600|info@anthera.com

Press Releases

 
Press Releases
  Date Title and Summary View
Dec 27, 2016
Sollpura narrowly missed the primary endpoint for change in the Coefficient of Fat Absorption (CFA) non-inferiority marginSollpura demonstrated non-inferiority in the per protocol CFA analysisSollpura demonstrated non-inferiority in Coefficient of Nitrogen Absorption (CNA) analysesAnthera will initiate a new study to demonstrate the efficacy of Sol...
Dec 13, 2016
HAYWARD, Calif., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that the Data Monitoring Committee (DMC) completed its pre-planned safety review of the SIMPLICITY clinical study of Sollpura supplied as a powder for oral solution in an initial cohort of cystic fibrosis patients  seven years of age and...
Dec 6, 2016
J. Craig Thompson promoted to Chief Executive Officer and appointed to the Board of DirectorsPaul F. Truex appointed as Executive Chairman of the BoardDr. Christopher Henney stepped down as Chairman of the Board but will remain as Director HAYWARD, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Today the Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) Boa...
Dec 6, 2016
Lower proteinuria in blisibimod versus placebo treated patientsChanges in circulating B-cells and serum immunoglobulins consistent with BAFF inhibition HAYWARD, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced positive trends from the Week 48 analysis of the Phase 2 BRIGHT-SC proof-of-concept...
Nov 22, 2016
Nov 10, 2016
Assessing next steps for blisibimod for the treatment of Systemic Lupus ErythematosusContinuing to explore blisibimod as treatment for IgA nephropathy - Phase 2 data in DecemberSollpuraTM SOLUTION phase 3 study in exocrine pancreatic insufficiency on track for topline data in December HAYWARD, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Anthera ...
Nov 4, 2016
Blisibimod topline data from the Phase 3 CHABLIS-SC1 Study in severe lupus patients is imminentData and Safety Monitoring Board recommendation to continue SOLUTION study with Sollpura™FDA Type C meeting in September validated basis for BLA filing and manufacturing approach for Sollpura™Closing of initial $17 million registered direct of...
Nov 2, 2016
HAYWARD, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that an abstract of the interim data from the Phase 2 BRIGHT-SC clinical study evaluating the treatment effect of blisibimod in patients with biopsy-proven IgA Nephropathy (IgAN) has been accepted as a late-breaking poster presentation a...
Nov 1, 2016
Sep 8, 2016
HAYWARD, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it has agreed to sell preferred convertible stock in two tranches to Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P. ("BVF"), and Rock Springs Capital for initial proceeds of $17.0 million with an option fo...
Page:
1
... NextLast
= add release to Briefcase
Print Friendly